215 related articles for article (PubMed ID: 27053681)
1. SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells.
Handle F; Erb HH; Luef B; Hoefer J; Dietrich D; Parson W; Kristiansen G; Santer FR; Culig Z
Mol Cancer Res; 2016 Jun; 14(6):574-85. PubMed ID: 27053681
[TBL] [Abstract][Full Text] [Related]
2. MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway.
Xiao C; Hong H; Yu H; Yuan J; Guo C; Cao H; Li W
Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):278-283. PubMed ID: 29658372
[TBL] [Abstract][Full Text] [Related]
3. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.
Liu C; Lou W; Armstrong C; Zhu Y; Evans CP; Gao AC
Prostate; 2015 Sep; 75(13):1341-53. PubMed ID: 25970160
[TBL] [Abstract][Full Text] [Related]
4. MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3.
Lin XM; Chen H; Zhan XL
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6906-6913. PubMed ID: 31486490
[TBL] [Abstract][Full Text] [Related]
5. MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway.
Li XD; Li XM; Gu JW; Sun XC
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5153-5159. PubMed ID: 29228427
[TBL] [Abstract][Full Text] [Related]
6. PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.
Itsumi M; Shiota M; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
J Mol Endocrinol; 2014 Aug; 53(1):31-41. PubMed ID: 24780839
[TBL] [Abstract][Full Text] [Related]
7. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
Wang C; Peng G; Huang H; Liu F; Kong DP; Dong KQ; Dai LH; Zhou Z; Wang KJ; Yang J; Cheng YQ; Gao X; Qu M; Wang HR; Zhu F; Tian QQ; Liu D; Cao L; Cui XG; Xu CL; Xu DF; Sun YH
Clin Cancer Res; 2018 Feb; 24(3):708-723. PubMed ID: 29191973
[No Abstract] [Full Text] [Related]
8. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
9. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
[TBL] [Abstract][Full Text] [Related]
10. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
[TBL] [Abstract][Full Text] [Related]
11. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I
Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973
[TBL] [Abstract][Full Text] [Related]
12. Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.
Shang AQ; Wu J; Bi F; Zhang YJ; Xu LR; Li LL; Chen FF; Wang WW; Zhu JJ; Liu YY
Cancer Biol Ther; 2017 May; 18(5):314-322. PubMed ID: 28448787
[TBL] [Abstract][Full Text] [Related]
13. The hepatitis C virus (HCV) protein, p7, suppresses inflammatory responses to tumor necrosis factor (TNF)-α
Convery O; Gargan S; Kickham M; Schroder M; O'Farrelly C; Stevenson NJ
FASEB J; 2019 Aug; 33(8):8732-8744. PubMed ID: 31163989
[TBL] [Abstract][Full Text] [Related]
14. The roles of SOCS3 and STAT3 in bacterial infection and inflammatory diseases.
Gao Y; Zhao H; Wang P; Wang J; Zou L
Scand J Immunol; 2018 Dec; 88(6):e12727. PubMed ID: 30341772
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647
[TBL] [Abstract][Full Text] [Related]
16. MiR-221 inhibits proliferation of pancreatic cancer cells via down regulation of SOCS3.
Xie J; Wen JT; Xue XJ; Zhang KP; Wang XZ; Cheng HH
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):1914-1921. PubMed ID: 29687843
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
[TBL] [Abstract][Full Text] [Related]
18. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.
Liu C; Zhu Y; Lou W; Cui Y; Evans CP; Gao AC
Prostate; 2014 Feb; 74(2):201-9. PubMed ID: 24307657
[TBL] [Abstract][Full Text] [Related]
20. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
